featured
Efficacy and Safety of Low-Dose IL-2 for Primary Sjögren Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial
JAMA Netw Open 2022 Nov 01;5(11)e2241451, J He, J Chen, M Miao, R Zhang, G Cheng, Y Wang, R Feng, B Huang, H Luan, Y Jia, Y Jin, X Zhang, M Shao, Y Wang, X Zhang, J Li, X Zhao, H Wang, T Liu, X Xiao, X Zhang, Y Su, R Mu, H Ye, R Li, X Liu, Y Liu, C Li, H Liu, F Hu, J Guo, W Liu, WB Zhang, A Jacob, JL Ambrus, C Ding, D Yu, X Sun, Z LiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.